Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Venetoclax with Ivosidenib or Enasidenib in AML
NCT04774393Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi, venetoclax, ivosidenib, enasidenib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started May 2021; status: recruiting.
02
Drugs
inqovivenetoclaxivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04774393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774393.